The IPSS -Score is a prognostic scoring system for myelodysplastic syndrome at diagnosis and without treatment; derived from a multivariate analysis of survival and freedom from progression to acute leukemia of 816 patients with de novo myelodysplastic syndrome. Medullary blasts % are taken from definition of WHO classification 2008 (MDS) rather then original publication, since ≥ 20 % blasts are corresponding to acute myeloid leukemia.
|Medullary blasts (%)||0–4||5–10||–||11–20||21–30|
|Number of cytopenias||0–1||2–3||–||–||–|
|Cytogenetic risk group||Low (normal karyotype, 5q-, 20q-, -Y)||Intermediate (all other aberrations)||High (complex karyotype ≥ 3 abnormalities, chromosome 7 anomalies)|
|Low risk||0 points|
|Intermediate-I risk||0.5–1 points|
|Intermediate-II risk||1.5–2 points|
|High risk||≥ 2.5 points|